Insmed Incorporated Insmed Incorporated

Insmed Incorporated

INSM

Rang in Aktien #1107
Insmed Incorporated operates as a biopharmaceutical enterprise focused on... Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions. The company's marketed treatment, ARIKAYCE, is administered to adult patients suffering from Mycobacterium avium complex (MAC) lung disease, serving as a component of a broader antibacterial drug regimen. In its development pipeline, Insmed is advancing Brensocatib, an oral and reversible inhibitor targeting dipeptidyl peptidase 1, which is being investigated for its potential in treating bronchiectasis and other disorders mediated by neutrophils. Additionally, the firm is developing Treprostinil Palmitil Inhalation Powder, an inhaled version of the treprostinil palmitil prodrug, designed to address pulmonary arterial hypertension and various other rare lung ailments. Founded in 1988, Insmed Incorporated maintains its primary corporate offices in Bridgewater, New Jersey.
Aktienkurs
$95.65
Zuletzt synchronisiert: 2026-10-19
Marktkapitalisierung
$20.89B
Veränderung (1 Tag)
-0.65%
Veränderung (1 Jahr)
-43.04%
Land
US
Handel Insmed Incorporated (INSM)

Kategorie

Healthcare
Aktien-Split-Historie für Insmed Incorporated (INSM)
Die Aktie Insmed Incorporated (Symbol: INSM) durchlief insgesamt 2 Aktiensplits.
Der letzte Aktiensplit fand am Mar 03, 2011 statt.
Eine INSM-Aktie, die vor dem Jul 31, 2000 gekauft wurde, entspricht heute 0.025 INSM-Aktien.
Liste der Aktiensplits
Jahr Aktien-Split Multiplikator Kumulierter Multiplikator
2011-03-03 1:10 x0.1 x0.025
2000-07-31 1:4 x0.25 x0.25
Aktiensplits ähnlicher Unternehmen oder Wettbewerber
Unternehmen Anzahl der Aktiensplits Kumulierter Multiplikator Land
1 x2
US
0 -
US
1 x3
AU
0 -
CH
0 -
NL